Sound waves may help deliver brain tumor drug

NCT ID NCT04446416

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This pilot study tested a device called NaviFUS that uses focused ultrasound to temporarily open the blood-brain barrier, combined with the drug bevacizumab (Avastin), in 6 patients with recurrent glioblastoma (a type of brain cancer). The goal was to see if the combination is safe and can slow tumor growth. Patients received the treatment after standard therapies had failed.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Bevacizumab (Avastin) combined with focused ultrasound (NaviFUS system)
What this could lead to
If successful, this approach could offer a new way to deliver drugs to brain tumors by temporarily opening the blood-brain barrier, potentially improving treatment for recurrent glioblastoma.
What could go wrong
This is a very early pilot study with only 6 participants, so results may not apply to a larger population. The treatment may not improve survival or could cause side effects from the ultrasound or drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Linkou Chang Gung Memorial Hospital

    Taoyuan City, 33305, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.